Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Nashville, Tennessee

Phase 1 cancer trials in Nashville, TN

173 Phase 1 cancer studies are recruiting participants at sites in Nashville as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 173 studies are recruiting at a site in Nashville.
  • By phase: Early Phase 1 (1), Phase 1 (88), Phase 1/2 (84).
  • By sponsor: industry (165), university, hospital or other (6), government (2).
  • By research area: Breast Cancer (64), Lung Cancer (61), Lymphoma (21), Prostate Cancer (13), Melanoma (10), Pancreatic Cancer (4).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Nashville

Basic details from each study's public record (the 30 most recently updated of 173). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Totus Medicines
    Study sites
    Sarah Cannon Cancer Center · Vanderbilt-Ingram Cancer Center
    Registry record
    NCT05683418 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study sites
    SCRI Oncology Partners · Vanderbilt Ingram Cancer Center
    Registry record
    NCT06253871 · updated
  3. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    SCRI Oncology Partners · Tennessee Oncology, Pllc
    Registry record
    NCT06324357 · updated
  4. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT05422794 · updated
  5. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Tennessee Oncology
    Registry record
    NCT06270706 · updated
  6. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    SCRI Oncology Partners Group
    Registry record
    NCT06638307 · updated
  7. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Greco Hainsworth Center for Research Tennessee Oncology · SCRI Oncology Partners
    Registry record
    NCT06827236 · updated
  8. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07503808 · updated
  9. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07652242 · updated
  10. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Tennessee Oncology PLLC · Vanderbilt University Medical Center
    Registry record
    NCT03424005 · updated
  11. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Sarah Cannon Research Institute (SCRI)
    Registry record
    NCT06586957 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Lung cancer studies recruiting in Nashville

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Sarah Canon Research Institute (SCRI) Oncology Partners
    Registry record
    NCT05786924 · updated
  2. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EpiBiologics
    Study site
    Sarah Cannon and HCA Research Institute
    Registry record
    NCT07462377 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07277413 · updated
  4. A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Tennessee Oncology, PLLC
    Registry record
    NCT07730021 · updated
  5. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT07903415 · updated
  6. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT03460977 · updated
  7. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Sarah Cannon Research Institute-Nashville-48456
    Registry record
    NCT04886804 · updated
  8. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Tennessee Oncology - Nashville Centennial Clinic
    Registry record
    NCT05099172 · updated
  9. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06914128 · updated
  10. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07020221 · updated
  11. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT07227597 · updated
  12. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT07090499 · updated
  13. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07491497 · updated
  14. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute- Pharmacy
    Registry record
    NCT07519655 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Lymphoma studies recruiting in Nashville

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT04726241 · updated
  2. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07520006 · updated
  3. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
    Registry record
    NCT07519772 · updated
  4. A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Umoja Biopharma
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07735533 · updated
  5. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Sarah Cannon
    Registry record
    NCT05384626 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call